Viz.ai has raised a $100 million funding round at a $1.2 billion valuation led by Tiger Global and Insight Partners, and followed by several of the company’s early backers including Scale Ventures, Kleiner Perkins, Threshold, GV (formerly Google Ventures), Sozo Ventures, CRV, and Susa.
The Series D round comes as the number of hospitals using the Viz Platform surpasses the 1,000 mark and patients served reaches millions. The new funds will be used to support Viz.ai’s significant growth trajectory, expand the Viz Platform to detect and triage additional diseases, and grow its customer base globally.
Viz.ai is committed to helping patients get better, faster and more equitable access to life saving treatments. We will continue to invest heavily in cutting edge technology and services to integrate deeply into the clinical workflow, allowing us to automate disease detection, increase diagnostic rates and enhance workflows across the entire hub and spoke health system. More patients receive the right treatment, resulting in better patient outcomes and improved financial efficiency for the health system.Chris Mansi, MD, Viz.ai co-founder and CEO
Viz.ai is leading the wave of innovation that applies AI to transform healthcare, creating a synchronized system of action for hospitals that delivers critical diagnostic data at decision-making moments and is clinically validated to improve patient care. Viz.ai solves the fundamental problem of connecting radiologists, emergency physicians, and primary care practitioners to the optimal specialists for a particular disease in order to facilitate care coordination and ensure optimized and consistent care pathways, reducing variability. It combines actionable computational diagnostics and precision medicine to make a significant improvement to patient outcomes and the financial efficiency of a health system. Viz.ai has pioneered the stroke detection and triage market with the de novo FDA clearance of its stroke module and was the first AI software to receive approval from CMS for NTAP (New Technology Add-on Payment). Customers include Mount Sinai Health System, Thomas Jefferson University, Banner Health, CommonSpirit Health, and HCA Healthcare, which is also an investor.
Viz.ai continues to expand its reach and innovation in additional disease states. Through its vast network of hospital and health system customers, Viz.ai assists in the care of one patient every 32 seconds. Over the past year, Viz.ai launched AI-driven solutions for aortic disease, pulmonary embolism, cerebral aneurysms, and is 510(k) pending for subdural hematoma. Viz.ai has seen great momentum in Europe, Middle East and Africa, with the company being awarded its first five CE Marks in 2021, followed by contracts with several leading hospitals. Viz.ai is hiring the best and brightest clinical, product, engineering and business minds to support and fuel its growth. With locations in San Francisco, Tel Aviv, Portugal and Amsterdam, the Viz.ai team has grown from 180 to more than 350 over the past 12 months, and is planning to grow by nearly 200 people over the next 12 months.
“Viz.ai is the stand out AI healthcare company; they are first-in-class in intelligent care coordination, with a solid foundation of clinical evidence supporting the value delivered to healthcare providers and patients,” said John Curtius, Partner at Tiger Global. “We see meaningful upside as the company expands to help life science companies expedite clinical trials and accelerate patient access to new effective treatments.”
The funding announcement follows the launch of Viz.ai’s groundbreaking AI-driven life science platform, a first-of-its-kind solution that revolutionizes the way medical device and pharmaceutical companies perform clinical trials and bring their treatments to market. Viz.ai has signed partnerships with several of the world’s largest life science companies. These companies are paying close attention as they increasingly look to digital health to complement and enhance traditional efforts.
“The Viz.ai platform has been the single most impactful advance I’ve seen as a physician, permitting the entire care team to mobilize immediately and deliver time sensitive treatment faster,” said Chris Kellner, MD, a cerebrovascular neurosurgeon in the Mount Sinai Health System in New York. “In addition, Viz Recruit permits us to automatically screen patients for clinical trial enrollment, ensuring we can offer cutting edge studies and treatments to more eligible patients.”
Nikhil Sachdev, managing director, Insight Partners, added, “Viz.ai excels beyond what’s in the market today with a demonstrably differentiated value proposition because Viz is embedded in clinical workflows, with extremely high engagement and wide adoption. We are excited to continue backing the company in this round after leading the Series C last year, as we are convinced Viz.ai will drive positive change in healthcare using AI, machine learning and sophisticated communication technologies that make a practical difference in therapeutic discovery and clinical practice. They are one of the fastest-growing companies in healthcare today.”
12 thoughts on “Viz.ai Raises $100 Million in Series D Funding”
Pingback: Viz.ai lève 100 millions de dollars en financement de série D - G-MedTech Français
Pingback: Viz.ai sammelt 100 Millionen US-Dollar in Serie-D-Finanzierung - G-MedTech Deutsch
Pingback: Viz.ai získává 100 milionů $ na financování série D - G-MedTech Čeština
Pingback: Viz.ai recauda $ 100 millones en fondos de la Serie D - G-MedTech Español
Pingback: Viz.ai raccoglie $ 100 milioni in finanziamenti di serie D - G-MedTech Italiano
Pingback: Viz.ai haalt $ 100 miljoen op in Series D-financiering - G-MedTech Nederlands
Pingback: Viz.ai zbiera 100 milionów dolarów w ramach finansowania serii D - G-MedTech Polski
Pingback: Viz.ai levanta US$ 100 milhões em financiamento da Série D - G-MedTech Português
Pingback: Viz.ai привлекает 100 миллионов долларов в рамках серии финансирования D - G-MedTech Pусский
Pingback: Viz.ai, D Serisi Finansman İçin 100 Milyon Dolar Artırdı - G-MedTech Türkçe
Pingback: Viz.ai, 시리즈 D 펀딩으로 1억 달러 모금 - G-MedTech 한국어
Pingback: Viz.aiはシリーズDの資金調達で1億ドルを調達 - G-MedTech日本語
Comments are closed.